Department of Pharmacology, School of Pharmacy, Qingdao University.
Biosci Trends. 2019;13(3):282-283. doi: 10.5582/bst.2019.01161.
Hepatocellular carcinoma (HCC) is a prevalent and refractory cancer in the world and very few drugs are available for the disease treatment currently. Programmed cell death protein-1 (PD-1) monoclonal antibodies including nivolumab and pembrolizumab has received accelerated approval for treatment of advanced HCC based on phase 1/2 clinical trials. However, the recently disclosed results of phase 3 clinical trials showed that both nivolumab and pembrolizumab as monotherapy failed to meet the primary objectives, which might overshadow the prospect of PD-1 inhibitors as monotherapy in treatment of advanced and unresectable HCC. The feasibility of PD-1 inhibitors in combination with other therapies or in other HCC settings requires further verification in the future.
肝细胞癌（HCC）是全球普遍存在且难以治疗的一种癌症，目前针对该疾病的治疗药物寥寥无几。程序性死亡蛋白-1（PD-1）单克隆抗体，包括纳武单抗和帕博利珠单抗，已基于 1/2 期临床试验获得加速批准，用于治疗晚期 HCC。然而，最近公布的 3 期临床试验结果显示，纳武单抗和帕博利珠单抗单药治疗均未能达到主要目标，这可能使 PD-1 抑制剂作为晚期不可切除 HCC 单药治疗的前景黯然失色。PD-1 抑制剂联合其他疗法或其他 HCC 治疗环境的可行性，未来还需要进一步验证。
